Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?

Clinical responses to anti-tumor monoclonal antibody (mAb) treatment have been regarded for many years only as a consequence of the ability of mAbs to destroy tumor cells by innate immune effector mechanisms. More recently, it has also been shown that anti-tumor antibodies can induce a long-lasting...

Descripción completa

Detalles Bibliográficos
Autores principales: Deligne, Claire, Milcent, Benoît, Josseaume, Nathalie, Teillaud, Jean-Luc, Sibéril, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557783/
https://www.ncbi.nlm.nih.gov/pubmed/28855903
http://dx.doi.org/10.3389/fimmu.2017.00950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557783/
https://www.ncbi.nlm.nih.gov/pubmed/28855903
http://dx.doi.org/10.3389/fimmu.2017.00950

Ejemplares similares